KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $19.6 billion.

  • Royalty Pharma's Liabilities and Shareholders Equity rose 767.21% to $19.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $74.9 billion, marking a year-over-year increase of 691.9%. This contributed to the annual value of $19.6 billion for FY2025, which is 767.21% up from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Liabilities and Shareholders Equity is $19.6 billion, which was up 767.21% from $19.3 billion recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Liabilities and Shareholders Equity peaked at $19.6 billion during Q4 2025, and registered a low of $15.9 billion during Q3 2023.
  • For the 5-year period, Royalty Pharma's Liabilities and Shareholders Equity averaged around $17.4 billion, with its median value being $17.6 billion (2021).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 1028.19% in 2023, then surged by 1379.15% in 2024.
  • Quarter analysis of 5 years shows Royalty Pharma's Liabilities and Shareholders Equity stood at $17.5 billion in 2021, then dropped by 4.01% to $16.8 billion in 2022, then decreased by 2.57% to $16.4 billion in 2023, then grew by 11.24% to $18.2 billion in 2024, then grew by 7.67% to $19.6 billion in 2025.
  • Its Liabilities and Shareholders Equity was $19.6 billion in Q4 2025, compared to $19.3 billion in Q3 2025 and $18.3 billion in Q2 2025.